CTSO: CytoSorbents reports 3rd quarter 2025 financial results. The company plans to submit a new De Novo application for Drug-Sorb ATR in early 2026. As a reminder
CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive...
184 Views
CTSO: CytoSorbents announced the De Novo denial on DrugSorb-ATR was upheld by the FDA. However
CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive...
157 Views
CTSO: CytoSorbents reports 2nd quarter 2025 financial results which exceeded our expectations. A decision on DrugSorb-ATR is expected from the FDA by the end of August 2025
CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive...
136 Views
CTSO: CytoSorbents reports 1st quarter 2025 financial and operating results which were largely in line with expectations. The company plans to appeal the FDA denial decision on DrugSorb-ATR.
CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive...
228 Views
CTSO: CytoSorbents provides a regulatory update for DrugSorb-ATR.
CytoSorbents is commercializing its E.U. approved CytoSorb blood purification technology to treat life-threatening conditions in the intensive...
255 Views